| 2026-05-29 |
详情>>
内部人交易：
Vance Cary Guy等共交易2笔
|
| 2026-05-14 |
详情>>
股本变动：
变动后总股本3077.67万股
变动原因 ▼▲
- 原因：
- From December 31,2025 to March 31,2026
Issuance of common stock due to exercise of penny warrants
Vesting of restricted stock units
|
| 2026-05-14 |
详情>>
业绩披露：
2026年一季报每股收益-0.35美元,归母净利润-1061.1万美元,同比去年增长23.44%
|
| 2026-05-14 |
财报披露：
美东时间 2026-05-14 盘后发布财报
|
| 2026-04-22 |
股东大会：
将于2026-06-03召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve for one-year terms on the Company’s board of directors (the “Board”) or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;
3.To approve, for the purposes of ASX Listing Rule 10.17 of the Australian Securities Exchange (the “ASX”) and the Company’s Amended and Restated Bylaws (the “Company’s Bylaws”) and for all other purposes, that the maximum aggregate annual cash fee pool from which the non-executive Directors of the Company may be paid for their services on the Board be increased from US$750,000 per annum to US$900,000 per annum;
4.To approve the grant of 22,214 restricted stock units to acquire shares of the Company’s common stock (“Common Stock”) and the grant of 16,133 options to acquire shares of Common Stock to Professor Suzanne Crowe on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
5.To approve the grant of 22,214 restricted stock units to acquire shares of Common Stock and the grant of 16,133 options to acquire shares of Common Stock to Jeremy Curnock Cook on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
6.To approve the grant of 22,214 restricted stock units to acquire shares of Common Stock and the grant of 16,133 options to acquire shares of Common Stock to Robert McNamara on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
7.To approve the grant of 22,214 restricted stock units to acquire shares of Common Stock and the grant of 16,133 options to acquire shares of Common Stock to Jan Stern Reed on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
8.To approve the grant of 26,250 restricted stock units to acquire shares of Common Stock and the grant of 19,063 options to acquire shares of Common Stock to Dr. Michael Tarnoff on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Dr. Tarnoff being appointed as a new non-executive Director of the Board effective August 6, 2025;
9.To approve the grant of 22,214 restricted stock units to acquire shares of Common Stock and the grant of 16,133 options to acquire shares of Common Stock to Dr. Michael Tarnoff on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
10.To approve the grant of 40,547 restricted stock units to acquire shares of Common Stock and the grant of 29,446 options to acquire shares of Common Stock to Joseph Woody on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Mr. Woody being appointed as a new non-executive Director of the Board effective January 1, 2026;
11.To approve the grant of 22,214 restricted stock units to acquire shares of Common Stock and the grant of 16,133 options to acquire shares of Common Stock to Joseph Woody on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
12.To approve, on an advisory basis, the compensation of our named executive officers;
13.To approve, on an advisory basis, the frequency of future advisory votes on executive compensation;
14.To approve, for the purpose of ASX Listing Rule 7.1 and all other purposes, the issuance of a warrant or warrants covering up to 650,000 shares of Common Stock, with a term of ten years (the “Warrants”), to Perceptive Credit Holdings V, LP (“Perceptive”), pursuant to the Credit Agreement between the Company and Perceptive, dated January 13, 2026 (the “Credit Agreement”), on the terms and conditions set forth in this Proxy Statement;
15.To approve, for the purpose of ASX Listing Rule 7.1A and all other purposes, the issue of Equity Securities (as defined in ASX Listing Rule 19.2) up to 10% of the issued capital (at the time of issuance) of the Company, calculated in accordance with ASX Listing Rule 7.1A.2, and on the terms and conditions set forth in this Proxy Statement.
|
| 2026-02-12 |
详情>>
业绩披露：
2025年年报每股收益-1.74美元,归母净利润-4858.7万美元,同比去年增长21.44%
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.37美元,归母净利润-3696.6万美元,同比去年增长26.44%
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-0.9美元,归母净利润-2377.9万美元,同比去年增长30.17%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.53美元,归母净利润-1385.9万美元,同比去年增长25.72%
|
| 2025-04-22 |
股东大会：
将于2025-06-04召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve for one-year terms or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending December 31, 2025;
3.To approve the grant of 10,022 restricted stock units to acquire shares of the Company’s common stock (“Common Stock”) and the grant of 4,295 options to acquire shares of Common Stock to Lou Panaccio on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
4.To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Suzanne Crowe on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
5.To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Jeremy Curnock Cook on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
6.To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Robert McNamara on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
7.To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Jan Stern Reed on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
8.To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Cary Vance on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
9.To approve the grant of 520,000 options to acquire shares of Common Stock to the Company’s Chief Executive Officer, James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
10.To approve, on an advisory basis, the compensation of our named executive officers;
11.To approve (a) the 2020 Omnibus Incentive Plan Amended and Restated (the “Plan”), the terms of which are summarized in this Proxy Statement; (b) for purposes of ASX Listing Rule 7.2 Exception 13(b), which provides an exception to ASX Listing Rule 7.1, the issuance of the Company’s equity securities under the Plan, in accordance with its terms and conditions, for a period of up to three years from the date of stockholder approval.
|
| 2025-02-13 |
详情>>
业绩披露：
2024年年报每股收益-2.39美元,归母净利润-6184.5万美元,同比去年增长-74.8%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.95美元,归母净利润-5025.6万美元,同比去年增长-77.48%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-1.32美元,归母净利润-3405.1万美元,同比去年增长-73.69%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.73美元,归母净利润-1865.8万美元,同比去年增长-102.36%
|
| 2024-04-23 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve for one-year terms or until their respective successors have been duly elected and qualified.
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending December 31, 2024.
3.To approve the grant of restricted stock units to acquire the Company's shares of common stock ("Common Stock") equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to $37,500 (at the time of the grant) to Mr. Lou Panaccio on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
4.To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to $37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
5.To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to $37,500 (at the time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
6.To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to $37,500 (at the time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
7.To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to $37,500 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
8.To approve the grant of restricted stock units to acquire shares of Common Stock equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock equal in value to $37,500 (at the time of the grant) to Mr. Cary Vance on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
9.To approve the grant of options to acquire 350,000 shares of Common Stock to the Company’s Chief Executive Officer, Mr. James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11.
10.Advisory vote to approve the compensation of the Company’s named executive officers.
11.To transact such other business as may properly come before the meeting.
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-1.4美元,归母净利润-3538.1万美元,同比去年增长-32.69%
|
| 2023-04-14 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve for a one-year term or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending December 31, 2023;
3.To approve the grant of restricted stock units to acquire shares of the Company’s Common Stock (which may be represented by CHESS Depositary Interests (“CDIs”)) equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $37,500 (at the time of the grant) to Mr. Lou Panaccio on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
4.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
5.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $37,500 (at the time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
6.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $37,500 (at the time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
7.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $147,000 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $63,000 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Mr. McNamara being appointed as a new director of the Company during 2023;
8.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $37,500 (at the time of the grant) to Mr. Robert McNamara on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
9.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $147,000 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $63,000 (at the time of the grant) to Mr. Cary Vance on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Mr. Vance being appointed as a new director of the Company during 2023;
10.To approve the grant of restricted stock units to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $87,500 (at the time of the grant) and the grant of options to acquire shares of Common Stock (which may be represented by CDIs) equal in value to $37,500 (at the time of the grant) to Mr. Cary Vance on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
11.To approve the grant of options to acquire 100,000 shares of common stock of the Company (which may be represented by CDIs) to the Company’s Chief Executive Officer, Mr. James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
12.To approve (a) an amendment to the 2020 Omnibus Incentive Plan (the “Plan), the terms of which are summarized in this Proxy Statement (the “Plan Amendment”); and (b) for purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, the issue of equity securities in the Company under and subject to the terms of the Plan within three years from the date that this proposal is approved by the Company’s stockholders as an exception to ASX Listing Rule 7.1;
13.To approve (a) the adoption of the Company’s Employee Stock Purchase Plan (the “ESPP”), the terms of which are summarized in this Proxy Statement; and (b) for the purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, the issue of equity securities in the Company under and subject to the terms of the ESPP within three years from the date that this proposal is approved by the Company’s stockholders as an exception to ASX Listing Rule 7.1;
14.Advisory vote to approve the compensation of the Company’s named executive officers;
15.To transact such other business as may properly come before the meeting or any adjournment or adjournments thereof.
|
| 2022-10-19 |
股东大会：
将于2022-12-12召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for a one-year term or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending December 31, 2022;
3.To amend the Company’s Certificate of Incorporation and Amended and Restated Bylaws to reduce the quorum requirement for stockholder meetings;
4.To approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Mr. Louis Panaccio on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
5.To approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
6.To approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
7.To approve the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
8.To approve the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$1,000,000 (at the time of the grant) to Mr. James Corbett on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
9.Advisory vote to approve the compensation of the Company’s named executive officers;
10.To transact such other business as may properly come before the meeting or any adjournment or adjournments thereof.
|
| 2021-11-09 |
股东大会：
将于2021-12-14召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve for a one-year term or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending June 30, 2022;
3.To approve amendments to the Company’s Amended and Restated Bylaws to insert provisions that will provide the Company with the right to implement a sales facility with respect to those CDI holders that hold at the relevant time less than a marketable parcel of the Company’s CDIs for the purposes of the ASX Listing Rules and ASX Settlement Operating Rules, on the terms and conditions set out in this Proxy Statement;
4.To ratify the issue of 3,214,250 shares of common stock in the capital of the Company with an issue price of US$21.50 per share that were issued pursuant to an underwritten registered public offering that was completed in March 2021, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 7.4 and for all other purposes;
5.To approve, for the purposes of ASX Listing Rule 10.17 and the Company’s Amended and Restated Bylaws and for all other purposes, that the maximum aggregate annual cash fee pool from which the non-executive directors of the Company may be paid for their services as members of the board of directors of the Company be increased from US$600,000 per annum to US$750,000 per annum;
6.To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. Louis Panaccio, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
7.To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Professor Suzanne Crowe, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
8.To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. Jeremy Curnock Cook, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
9.To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. Louis Drapeau, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
10.To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Mr. James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
11.To approve the grant of restricted stock units to acquire 8,675 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 4,925 shares of common stock of the Company (which may be represented by CDIs) to Mr. James Corbett, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Mr. James Corbett being appointed as a new director of the Company during 2021;
12.To approve the grant of restricted stock units to acquire 4,350 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 2,550 shares of common stock of the Company (which may be represented by CDIs) to Ms. Jan Stern Reed, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
13.To approve the grant of restricted stock units to acquire 8,675 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 4,925 shares of common stock of the Company (which may be represented by CDIs) to Ms. Jan Stern Reed, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, in recognition of Ms. Jan Stern Reed being appointed as a new director of the Company during 2021;
14.To approve the grant of restricted stock units to acquire 95,280 shares of common stock of the Company (which may be represented by CDIs) and the grant of options to acquire 55,200 shares of common stock of the Company (which may be represented by CDIs) to the Company’s Chief Executive Officer, Dr. Michael Perry, on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11;
15.Advisory vote to approve the compensation of the Company’s named executive officers;
16.To transact such other business as may properly come before the meeting or any adjournment or adjournments thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-02-25 |
复牌提示：
2021-02-24 18:10:25 停牌，复牌日期 2021-02-25 06:45:00
|
| 2020-11-02 |
股东大会：
将于2020-10-29召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for a one-year term or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending June 30, 2021;
3.To approve: (a) the adoption of the AVITA Therapeutics, Inc. 2020 Omnibus Incentive Plan (the “Plan”), the terms of which are summarized in this Proxy Statement; and (b) for the purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, the issue of equity securities in the Company under and subject to the terms of the Plan for three years commencing on the date that the Plan is approved by the Company’s stockholders;
4.To approve, for the purposes of ASX Listing Rule 10.17 and the Company’s Amended and Restated Bylaws and for all other purposes, that the maximum aggregate annual cash fee pool from which non-executive directors of the Company may be paid for their service as a member of the board of directors of the Company be increased from A$450,000 per annum to US$600,000 per annum;
5.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Mr. Louis Panaccio (or his nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to him by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
6.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Professor Suzanne Crowe (or her nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to her by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
7.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Mr. Louis Drapeau (or his nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to him by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
8.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Mr. Jeremy Curnock Cook (or his nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to him by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
9.Advisory vote to approve the compensation of our named executive officers;
10.Advisory vote to approve the frequency of future advisory votes to approve of executive compensation;
11.To transact such other business as may properly come before the meeting or any adjournment or adjournments thereof.
|
| 2020-11-02 |
股东大会：
将于2020-11-09召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve for a one-year term or until their respective successors have been duly elected and qualified;
2.To ratify the appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending June 30, 2021;
3.To approve: (a) the adoption of the AVITA Therapeutics, Inc. 2020 Omnibus Incentive Plan (the “Plan”), the terms of which are summarized in this Proxy Statement; and (b) for the purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, the issue of equity securities in the Company under and subject to the terms of the Plan for three years commencing on the date that the Plan is approved by the Company’s stockholders;
4.To approve, for the purposes of ASX Listing Rule 10.17 and the Company’s Amended and Restated Bylaws and for all other purposes, that the maximum aggregate annual cash fee pool from which non-executive directors of the Company may be paid for their service as a member of the board of directors of the Company be increased from A$450,000 per annum to US$600,000 per annum;
5.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Mr. Louis Panaccio (or his nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to him by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
6.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Professor Suzanne Crowe (or her nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to her by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
7.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Mr. Louis Drapeau (or his nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to him by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
8.To approve, subject to the passing of Proposal No. 3, the issue of shares of common stock or CHESS Depositary Interests in the Company to Mr. Jeremy Curnock Cook (or his nominee) up to a value of US$8,333 in each fiscal year during the three year period from the date of this Annual Meeting (being in aggregate up to a value of US$24,999) under the Company’s 2020 Omnibus Incentive Plan, in lieu of the equivalent amount of directors fees otherwise payable to him by the Company, on the terms and conditions as set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.14;
9.Advisory vote to approve the compensation of our named executive officers;
10.Advisory vote to approve the frequency of future advisory votes to approve of executive compensation;
11.To transact such other business as may properly come before the meeting or any adjournment or adjournments thereof.
|
| 2020-06-30 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2019-11-01 |
股东大会：
将于2019-11-26召开股东大会
会议内容 ▼▲
- 1.ADOPTION OF REMUNERATION REPORT
2.RE-ELECTION OF DIRECTOR – SUZANNE CROWE
3.RE-ELECTION OF DIRECTOR – LOUIS DRAPEAU
4.RE-ELECTION OF DIRECTOR – DAMIEN MCDONALD
5.APPROVAL OF THE EMPLOYEE SHARE PLAN
6.APPROVAL OF THE ISSUE OF LONG TERM INCENTIVE RIGHTS TO DR MICHAEL PERRY
|